Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series

This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis. In every case, dupilumab facial redness subsided without discontinuation of dupilumab within 3 months after onset.

Detalles Bibliográficos
Autores principales: Hara, Shuhei, Itonaga, Takaaki, Nishino, Makoto, Yanagida, Noriyuki, Sato, Sakura, Ebisawa, Motohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509969/
https://www.ncbi.nlm.nih.gov/pubmed/37780793
http://dx.doi.org/10.1016/j.jacig.2023.100096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509969/
https://www.ncbi.nlm.nih.gov/pubmed/37780793
http://dx.doi.org/10.1016/j.jacig.2023.100096

Ejemplares similares